Genomics and clinical research for breast cancer;Génomique et recherche clinique en cancérologie mammaire

Medecine/Sciences

Volumn 28, Issue SPEC. ISSUE 1, 2012, Pages 14-18

  Bertucci, François ^a,b   Birnbaum, Daniel ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

BREAST TUMOR; CARCINOMA; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HUMAN; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; ONCOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; CARCINOMA; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MEDICAL ONCOLOGY; PROGNOSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84860847329     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/201228s105     Document Type: Review

References (33)

1. Bertucci F, Houlgatte R, Nguyen C, et al. Gene expression profiling of cancer by use of DNA arrays: How far from the clinic? Lancet Oncol 2001 ; 2 : 674-82. (Pubitemid 33085813)
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 ; 406 : 747-52.
3. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 ; 98 : 10869-74. (Pubitemid 32878711)
4. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 2004 ; 10 : 5508-17. (Pubitemid 39100489)
5. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005 ; 65 : 9155-8. (Pubitemid 41507977)
6. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005 ; 65 : 2170-8. (Pubitemid 40490124)
7. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudinlow intrinsic subtype of breast cancer. Breast Cancer Res 2010 ; 12 : R68.
8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009 ; 360 : 790-800.
9. Bertucci F, Finetti P, Cervera N, Birnbaum D. Classification pronostique du cancer du sein et profils d'expression génique sur puces à ADN. Med Sci (Paris) 2008 ; 24 : 599-606 (Pubitemid 352026911)
10. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002 ; 415 : 530-6. (Pubitemid 34130608)
11. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002 ; 347 : 1999-2009. (Pubitemid 35461656)
12. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006 ; 98 : 1183-92. (Pubitemid 44390989)
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817-26. (Pubitemid 40051905)
14. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 ; 5 : 607-16. (Pubitemid 38748922)
15. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006 ; 98 : 262-72. (Pubitemid 43264710)
16. Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 ; 24 : 4236-44. (Pubitemid 46630780)
17. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011 ; 29 : 1578-86.
18. Bertucci F, Borie N, Roche H, et al. Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2011 ; 127 : 363-73.
19. Gravier E, Pierron G, Vincent-Salomon A, et al. A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 2010 ; 49 : 1125-34.
20. Zhang Y, Martens JW, Yu JX, et al. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res 2009 ; 69 : 3795-801.
21. Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011 ; 3 : 153-66.
22. Mills RE, Walter K, Stewart C, et al. Mapping copy number variation by population-scale genome sequencing. Nature 2011 ; 470 : 59-65.
23. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009 ; 41 : 579-84.
24. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010 ; 28 : 4674-82.
25. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 66 : 3992-5.
26. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 2008 ; 26 : 729-35. (Pubitemid 351264385)
27. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 ; 26 : 721-8. (Pubitemid 351264384)
28. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010 ; 16 : 5351-61.
29. Bertucci F, Ferrero JM, Bachelot T, et al. SA02 trial: A genomics-based prospective study of adjuvant chemotherapy in node-positive early breast cancer with good-prognosis signature. San Antonio, TX: Breast Cancer Symposium, 2009.
30. Bild AH, Parker JS, Gustafson AM, et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res 2009 ; 11 : R55.
31. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010 ; 28 : 4877-83.
32. Andre F, Delaloge S, Soria JC. Biology-driven phase II trials: What is the optimal model for molecular selection? J Clin Oncol 2011 ; 29 : 1236-8.
33. Tursz T, Andre F, Lazar V, LaCroix L, Soria JC. Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 2011 ; 8 : 177-83.